Related Experiment Video
Updated: Nov 6, 2025

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
Precision oncology for breast cancer through clinical trials
Aurora S Blucher1, Gordon B Mills1, Yiu Huen Tsang2
1Oregon Health & Science University, Oregon, USA.
Abstract:
Precision treatment for breast cancers has made several notable advances in recent decades, but challenges of tumor heterogeneity, drug resistance, and aggressive recurrence and metastases remain. To meet and overcome these challenges, we must refine our understanding of breast subtypes and treatment biomarkers according to the knowledge afforded across the spectrum of 'omics assays. A critical aspect of harnessing this knowledge into actionable biomarkers for treatment decision relies on our ability to integrate knowledge across data types and leverage our insight in evidence-based clinical trials. We review recent advances in cutting-edge clinical trials for precision treatment of breast cancer, including chemotherapies, targeted therapies, immunotherapies, and combination therapies. We comment on promising future areas of development for this exciting point in precision breast cancer research.
Insights
Advances in precision breast cancer treatment face challenges like tumor heterogeneity and drug resistance. Integrating
Area of Science:
- Oncology
- Genomics
- Biomarker Discovery
Background:
- Precision medicine has advanced breast cancer treatment, yet challenges persist.
- Tumor heterogeneity, drug resistance, and metastasis require deeper understanding.
- Current 'omics assays offer insights into breast cancer subtypes and biomarkers.
Purpose of the Study:
- To review recent clinical trials for precision breast cancer treatment.
- To highlight advances in chemotherapy, targeted therapy, and immunotherapy.
- To discuss future directions in precision breast cancer research.
Main Methods:
- Review of cutting-edge clinical trials in precision breast cancer.
- Analysis of data integration across different 'omics assays.
- Synthesis of knowledge for actionable biomarker development.
Main Results:
- Notable advances in precision breast cancer therapies have been achieved.
- Integration of multi-omics data is crucial for developing treatment biomarkers.
- Clinical trials are exploring novel chemotherapies, targeted therapies, and immunotherapies.
Conclusions:
- Continued research into breast cancer subtypes and biomarkers is essential.
- Integrating diverse data types is key to overcoming treatment resistance.
- Future clinical trials hold promise for improved precision breast cancer care.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Clinical Trials: Overview
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

